T-cell Therapy Market Size to Worth Around US$ 20.8 Billion by 2030

According to Vision Research Reports, the global T-cell therapy market size is expected to be worth around US$ 20.8 billion by 2030 from valued at US$ 4.9 billion in 2021 and is anticipated to grow at a CAGR of 20.4% during forecast period 2022 to 2030.

Report Takeaway

• North America accounted for the largest revenue share of around 41% in 2021
• Asia-Pacific is projected to witness the fastest CAGR with emerging markets such as China at the forefront
• In 2021, the hematologic malignancies indication segment accounted for a 51% revenue share.
• In 2021, CAR T-cell therapy type segment accounted for the largest revenue share of 83% in 2021
• By Modality, the research segment dominated accounted 76% of revenue share in 2021

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37426

The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.

The market is favored by the development of CAR T-cell therapy for several clinical areas such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications. The increase in the geriatric population and the increasing number of lymphoma and leukemia cases across the globe are expected to translate into a significantly higher demand for the CAR T-cell therapy market.

Furthermore, the companies are investing huge amounts in research and development of CAR T-cell therapy either as a monotherapy or as combination therapy. The clinical trial landscape of various hematologic cancers has been on the rise in recent years, and this will fuel the CAR T-cell therapy market in the future.

Within the research report, the market is segmented based on application, target antigen, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Growth Factors

The milestone approvals of Kymriah and Yescarta along with the recent approval of Tecartus have bolstered the exponential revenue growth in the market.

The commercial launch of these innovative therapies across various regions has spurred the investment flow in this arena thereby driving the market. Cancer indications are the major investment targets for the key operating players. However, space is constantly expanding to include other indications such as viral infections, creating lucrative opportunities for the operating players.

Engineered T-cell marketspace is characterized by an in-depth network of several entities marked by financially, academically, and licensing agreements. Collaborations between research bodies and manufacturers to assess the efficacy and safety of therapies are anticipated to put forth the advancements in the space, thereby expected to result in the anticipated success of the market.

By far, the wider application of CAR-T therapies has been hampered by the considerable lack of efficiency to treat solid tumors and linked toxicity concerns due to the strong immunosuppressive tumor microenvironment. Thus, operating players are engaged in implementing new approaches to overcome these challenges and expand the application in solid.

Scope of the Report

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37426

Modality Insights

The research segment dominated the market for T-cell therapy and accounted for more than 75.0% of revenue share in 2020 owing to the high number of products in the clinical development phase. A substantial number of research institutes such as Mayo Clinic are actively engaged in conducting CAR-T therapy programs thus supporting the method as a preferable method of cancer management.

Several operating entities are collaborating with research communities across the globe, resulting in the shift in focus on accelerating the development of CAR-T therapies to expand the therapeutic application landscape. For instance, in October 2020 Immuneel Therapeutics collaborated with Institutd’InvestigacionsBiomèdiques August Pi iSunyer and Hospital Clínic de Barcelona for the development and commercialization of CAR-T therapy in India.

On the other hand, regulatory bodies are making focused efforts to propel the commercial use of these therapies in clinical and hospital settings. In August 2020, the Centers for Medicare and Medicaid Services (CMS) policies for reimbursement and coverage of CAR-T cell therapy. This policy increased the payment received to 65% of the total cost. This would spur commercial revenue growth.

Therapy Type Insights

In 2020, CAR T-cell therapy segment dominated the market for T-cell therapy and accounted for the largest revenue share of 82.0% in 2020. This is owing to the exponential rise in the number of clinical trials for CAR-T therapies and the increasing involvement of key players in this arena. A substantial number of new entrants and academic institutions are conducting clinical trials for CAR-T therapeutic products for different as well as same indications, consequently supporting the dominance of the segment.

Advancements in CAR-T therapy manufacturing enhanced the uptake of these therapies in the treatment of various cancers. The emergence of new approaches such as second-generation, next-generation CAR-T immunotherapy may overcome the challenges like resistance, side effects thus, leading to growth in organic revenue generation.

Besides this, T-cell receptor-based therapies pegged the second position in the global space owing to their potential in the treatment of solid tumors. This segment is gaining significant attention for the treatment of melanoma. Adaptimmune is one of the companies that focuses on TCR therapy for melanoma in collaboration with GlaxoSmithKline.

Indication Insights

In 2020, the hematologic malignancies segment dominated the market for T-cell therapy and accounted for a 49.0% revenue share. The CAR-T-cell therapies have been predominantly used to treat hematological malignancies including lymphoma, leukemia, and myeloma. Given the high number of market entities entering the market and high fixed costs of autologous cell manufacturing, the segment is expected to witness high market competition in the near future.

The CAR-T cell therapies have made remarkable advancements in hematological malignancies, resulting in segment saturation in terms of number of market players operating in the segment. As a result, several competitors are now shifting their focus on the development of treatments for solid tumors to capitalize on the untapped avenues of the market. The development of affordable and effective therapy for solid tumors presents lucrative opportunities for the operating key stakeholders.

Viral infections such as COVID-19 and HIV have expanded the landscape of T-cell therapies. Several CARs targeting viral infections have made tremendous progress in recent years. Anti-HIV CAR-T cell therapy has reached clinical trial whereas others such as HCV, HBV are in pre-clinical development. This is anticipated to spur the revenue flow in non-cancer indications.

Regional Insights

North America dominated the T-cell therapy market and accounted for the largest revenue share of around 40.0% in 2020. The presence of strong research, as well as a commercial base coupled with a high number of clinical trials being conducted for T-cell therapies in the U.S., has majorly contributed to the dominance of the market in the region.

Furthermore, the increasing number of regulatory approvals in the U.S. and Canada along with the changing reimbursement scenario in the region has also accelerated the uptake of these therapies leading to significant market growth. In addition, the presence of a substantial number of medical centers offering CAR-T cell therapies also supports the regional market growth.

In recent years, China has emerged as a potential market for CAR-T therapies with the highest number of registered clinical trials pertaining to these therapies. Focused efforts on government investment and reforms in the country have resulted in significant growth consequently exhibiting the fastest CAGR in the region.

Key Players

• Novartis AG
• Merck KGaA
• Gilead Sciences Inc.
• TCR2 Therapeutics Inc
• Bluebird Bio Inc.
• Sorrento Therapeutics
• Fate Therapeutics
• Pfizer Inc.
• Amgen
• Celgene Corporation

Market Segmentation

• Modality Outlook
  • Research
  • Commercialized
• Therapy Type Outlook
  • CAR T-cell Therapy
  • T Cell Receptor (TCR)-based
  • Tumor Infiltrating Lymphocytes (TIL)-based
• Indication Outlook
  • Hematologic Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma
  • Solid Tumors
    • Melanoma
    • Brain & Central Nervous System
    • Liver Cancer
    • Others
  • Others
• Regional Outlook
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37426

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333